SYSTEMATIC FORMULATION DEVELOPMENT OF IMMEDIATE RELEASE TABLET DOSAGE FORM USING QUALITY BY DESIGN APPROACH

被引:0
|
作者
Saxena, Namrata [1 ]
Shrivastava, Birendra [1 ]
机构
[1] Mylan Labs Ltd, Jinnaram Mandal, Andhra Pradesh, India
关键词
Model antibacterial drug BCS II; Immediate release tablet; Wet granulation; Quality by Design; statistical design of experiments; Design Space;
D O I
10.13040/IJPSR.0975-8232.4(8).3110-24
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The main goal of this study was to develop a stable formulation of model antibacterial drug as an immediate-release tablet systematically using Quality by Design approach of which design of experiments is an integral part. The model drug was found to be a BCS class II drug official in USP having a plasma half-life of three to four hours. The formulation development work was initiated with wet granulation method and a total of three trials were conducted to determine the critical material attributes of the formulation used as factors for the experimental designs. The binder (Povidone K29/32,), Superdisintegrant (Crosscarmellose Sodium), Lubricant (Stearic acid and magnesium stearate), Pregelatinized Starch 1500 (binder and disintegrant) were determined to be critical for the formulation of the model antibacterial drug. A fractional factorial design (FFD) for four factors at two levels was selected to screen the varied response variable. A total of eight trials were conducted (24-1FFD). The four factors viz. Povidone K29/32 (X1), Crosscarmellose Sodium (X2), lubricant ratio (X3) and Pregelatinised starch 1500 IG: EG (X4) were varied as required by the experimental design and the factor levels were coded. (+1 for high and -1 for low). Disintegration time was taken as response variable. A central composite design (CCD) for two factors at three levels was selected to optimize the varied response variable. A total of thirteen trials were conducted. The two factors viz. PovidoneK29/32 (X1), Crosscarmellose Sodium (X2), were varied as required by the experimental design and the factor levels were coded. (+1 for high, 0 for moderate and -1 for low). Friability (5) and in vitro % drug release in 5 minutes (Q5) were taken as response variables. The formulated tablets were evaluated for various precompression parameters like bulk density, tapped density, Carr's index, Hausner's ratio and post compression parameters like thickness, hardness, weight variation, friability, disintegration test and in vitro drug release studies. From this study, it was concluded that optimized formulation containing Crosscarmellose Sodium (8.16%) and Povidone K29/32 (1.37%) showed satisfactory friability, in vitro % drug release at 5 mins (Q5) and other physical characteristics of immediate release tablets. A design space was created using desired levels of response variables. A composition was selected within design space as optimized formulation and internally validated. Linear correlation plots were drawn for the predicted and observed responses.
引用
收藏
页码:3110 / 3124
页数:15
相关论文
共 50 条
  • [31] An integrated, quality by design (QbD) approach for design, development and optimization of orally disintegrating tablet formulation of carbamazepine
    Mishra, Saurabh M.
    Rohera, Bhagwan D.
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2017, 22 (07) : 889 - 903
  • [32] Optimization of the Extragranular Excipient Composition of Paracetamol Tablet formulation using the Quality by Design Approach
    Apeji, Yonni Eshovo
    Ariko, Naima Avosuahi
    Olayemi, Olubunmi Jumoke
    Olowosulu, Adeniji Kehinde
    Oyi, Avosuahi Rukayat
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 58
  • [33] Scalable Design and Development of Modified Release Hydrochlorothiazide Formulation Employing Quality by Design Approach
    Singhai, V. D.
    Sharma, S.
    Paliwal, S.
    Maheshwari, R.
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 84 (04) : 910 - 928
  • [34] Development and evaluation of modified release wax matrix tablet dosage form for tramadol hydrochloride
    Mahaparale, Paresh Ramesh
    Kuchekar, Bhanudas Shankarrao
    ASIAN JOURNAL OF PHARMACEUTICS, 2015, 9 (02) : 102 - 106
  • [35] Formulation Development and Evaluation of Tablet in Tablet Dosage form to Proffer a Quick and Protracted Relief in Gastritis and Allied Gastric Disorders
    Kanwar, Kapil
    Narang, R. K.
    ASIAN JOURNAL OF PHARMACEUTICS, 2023, 17 (03) : 529 - 543
  • [36] FORMULATION AND EVALUATION OF IMMEDIATE RELEASE TABLET OF LAMIVUDINE, ZIDOVUDINE AND NEVIRAPINE
    Thota, Srikanth
    Radhalakshmi, A. K.
    Krishnanrajan, D.
    Parthiban, K. G.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2011, 2 (07): : 1772 - 1777
  • [37] DEVELOPMENT OF A NEW HIGH-PERFORMANCE THIN LAYER CHROMATOGRAPHIC METHOD FOR QUANTITATIVE ESTIMATION OF LAMIVUDINE AND ZIDOVUDINE IN COMBINED TABLET DOSAGE FORM USING QUALITY BY DESIGN APPROACH
    Gopani, Mehul
    Patel, Rashmin B.
    Patel, Mrunali R.
    Solanki, Ajay B.
    JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2014, 37 (17) : 2420 - 2432
  • [38] Development andin vitro/in vivoevaluation of a novel benznidazole liquid dosage form using a quality-by-design approach
    Santos Souza, Higo Fernando
    Real, Daniel
    Leonardi, Dario
    Rocha, Sandra Carla
    Alonso, Victoria
    Serra, Esteban
    Silber, Ariel Mariano
    Javier Salomon, Claudio
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2017, 22 (12) : 1514 - 1522
  • [39] Synthesis of Celecoxib-Eutectic Mixture Particles via Supercritical CO2 Process and Celecoxib Immediate Release Tablet Formulation by Quality by Design Approach
    Hong, Seung-Hyeon
    Dinh, Linh
    Abuzar, Sharif Md
    Lee, Eun Seok
    Hwang, Sung-Joo
    PHARMACEUTICS, 2022, 14 (08)
  • [40] QbD method to the formulation and development of a spironolactone immediate-release tablet with enhanced dissolving research
    Bayas, Jayendrasingh P.
    Sumithra, M.
    MATERIALS TODAY-PROCEEDINGS, 2022, 51 : 2539 - 2549